Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;9(1):33-45.
doi: 10.1177/1758834016667179. Epub 2016 Sep 16.

Incorporating VEGF-targeted therapy in advanced urothelial cancer

Sujata Narayanan  1 , Sandy Srinivas  2
Affiliations
Review

Incorporating VEGF-targeted therapy in advanced urothelial cancer

Sujata Narayanan et al. Ther Adv Med Oncol. 2017 Jan.

Abstract

Patients with relapsed or refractory urothelial carcinoma (UC) have poor prognosis coupled with few options for systemic treatment. The role of angiogenesis in the evolution of cancers has been established, and studies have shown that it plays a key role in the pathogenesis of UC. Many targeted agents have been used in phase I-II trials for the treatment of UC, with encouraging but modest results. Recently, studies combining angiogenesis inhibitors with other chemotherapeutic agents were able to achieve objective responses higher than most commonly used second-line therapies in UC. Future efforts in investigating these therapies in UC rely on identification of biomarkers and other predictors of response to anti-VEGF therapy.

Keywords: angiogenesis; antibody; small molecules; urothelial cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

    1. Abou-Alfa G., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293–4300. - PubMed
    1. Adnane L., Trail P., Taylor I., Wilhelm S. (2006) Sorafenib (BAY 43–9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407: 597–612. - PubMed
    1. Aldebasi Y., Rahmani A., Khan A., Aly S. (2013) The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy. Int J Clin Exp Med 6: 239–251. - PMC - PubMed
    1. Balar A., Apolo A., Ostrovnaya I., Mironov S., Iasonos A., Trout A., et al. (2013) Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol 31: 724–730. - PMC - PubMed
    1. Barnhill R., Piepkorn M., Cochran A., Flynn E., Karaoli T., Folkman J. (1998) Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch Dermatol 134: 991–994. - PubMed

LinkOut - more resources